PRISModegib: the use of the PRISM test to assess the Health‐Related Quality of Life of patients with Locally Advanced Basal Cell Carcinoma undergoing Hedgehog Pathway Inhibitor Therapy

Abstract

Vismodegib is an Hedgehog Pathway Inhibitor Therapy (HPIT) for patients affected by Locally Advanced Basal Cell Carcinoma (laBCC) and Metastatic Basal Cell Carcinoma (mBCC) not eligible for surgery and/or radiotherapy^1‐4. The efficacy of Vismodegib has been reported by several studies; likewise, treatment‐emergent adverse effects (AEs) have been reported for 95‐100% of the patients⁵. It has been observed that patients who achieved complete or partial response often discontinued HPIT because of a grade 1 or 2 AEs.

This article is protected by copyright. All rights reserved.

http://bit.ly/2BtjM0e